Umbilical cord mesenchymal stem cell therapy - Asia Stem Cell Regenerative Pharmaceutical
Alternative Names: UC-MSC infusion - Asia Stem Cell Regenerative PharmaceuticalLatest Information Update: 14 Aug 2023
At a glance
- Originator Asia Pharmaceuticals
- Class Mesenchymal stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Liver cirrhosis
Most Recent Events
- 09 Aug 2023 Asia Cell Therapeutics plans a phase I trial for Adult respiratory distress syndrome in China (IV) in August 2023 (NCT05983627)
- 19 Jul 2023 Asia Cell Therapeutics plans a phase I trial in Ankylosing Spondylitis (Treatment-experienced) in July 2023 (IV, Injection) (NCT05962762)
- 04 Nov 2021 Clinical trials in Liver cirrhosis (In adults) in China (IV) in November 2021 (NCT05106972)